Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Publication/Presentation Date
5-1-2023
Abstract
BACKGROUND: CLASSIC-MS evaluated the long-term efficacy of cladribine tablets in patients with relapsing multiple sclerosis.
OBJECTIVE: Report long-term mobility and disability beyond treatment courses received in CLARITY/CLARITY Extension.
METHODS: This analysis represents CLASSIC-MS patients who participated in CLARITY with/without participation in CLARITY Extension, and received ⩾1 course of cladribine tablets or placebo (
RESULTS: At CLASSIC-MS baseline, mean ± standard deviation EDSS score was 3.9 ± 2.1 and the median time since LPSD was 10.9 (range = 9.3-14.9) years. Cladribine tablets-exposed population: 90.6% (
CONCLUSION: With a median 10.9 years' follow-up after CLARITY/CLARITY Extension, findings suggest the sustained long-term mobility and disability benefits of cladribine tablets.
Volume
29
Issue
6
First Page
719
Last Page
730
ISSN
1477-0970
Published In/Presented At
Giovannoni, G., Boyko, A., Correale, J., Edan, G., Freedman, M. S., Montalban, X., Rammohan, K., Stefoski, D., Yamout, B., Leist, T., Aydemir, A., Borsi, L., & Verdun di Cantogno, E. (2023). Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple sclerosis (Houndmills, Basingstoke, England), 29(6), 719–730. https://doi.org/10.1177/13524585231161494
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
37012898
Department(s)
Administration and Leadership
Document Type
Article